News

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

These subgroup analysis findings on icotrokinra indicate that the drug is safe and effective among adolescents and adults with moderate-to-severe psoriasis.

VERVE-102 is targeting the reduction of LDL-C levels among individuals with hyperlipidemia and high lifetime cardiovascular risk.

Lafayette describes ongoing unmet needs in IgAN care and how the growing understanding of disease pathogenesis has informed drug development.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

These data highlight the potential impacts of baricitinib across significant hair-bearing areas involved in alopecia areata.

Vega discussed recent efforts in the public health field and his own center that have helped to improve screening rates.

Most patients preferred OLC over their previous phosphate binder, and pill number and size were identified as barriers to phosphate binder adherence.

Tailor discusses the future of AI in ophthalmology and beyond, and some of the challenges it may bring.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.

This retrospective, real-world analysis highlights several notable findings on JAK inhibitor use among patients with alopecia areata.

Electronic health interventions improved medication adherence in kidney transplant recipients, with potential implications for improving patient outcomes.

Herzig outlined a talk she gave at the ACP Internal Medicine 2025 meeting reviewing the latest data in acute inpatient pain management.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

In this interview, Chovatiya highlighted the unmet needs of patients with atopic dermatitis and the ways in which nemolizumab’s FDA approval addresses them.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

Gelles discussed AI tools that are becoming a part of clinician’s armamentariums and the impact they are having on the field.

Study findings suggest significant socioeconomic disparities in preemptive kidney transplantation rates in children and the need for targeted interventions.

Investigators examined the safety of the recalled sickle cell disease medication through retrospective analysis of an FDA database.

Assigned a PDUFA target date of August 27, 2025, the resubmitted application for the wet AMD treatment will offer another chance for US approval.

Hoang discussed the CARD initiative started at Wayne State University in Detroit that she presented at the ACP IM 2025 meeting.

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.

Test your knowledge below on pooled data from the ARCADIA 1 and 2 trials and stay up to date with clinical advancements in atopic dermatitis.

An analysis of data from 2 PBC and PSC cohorts suggests fatigue is common, especially in females with PBC, and may be influenced by pruritus.

Our Q1 2025 recap for ophthalmology spotlights 5 regulatory updates, 5 key trial announcements, and two episodes of our flagship ophthalmology podcast.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

In our Q1 recap for dermatology, we spotlight clinical trial data, recent updates, and advancements in therapeutic options.

Q1 2025 sleep updates include FDA rejecting pitolisant NDA for idiopathic hypersomnia, iptacopan improving PNH fatigue, and more.